| Literature DB >> 28729000 |
Stéphane Mouraux1, Eric Bernasconi2, Céline Pattaroni1, Angela Koutsokera1, John-David Aubert1, Johanna Claustre3, Christophe Pison3, Pierre-Joseph Royer4, Antoine Magnan4, Romain Kessler5, Christian Benden6, Paola M Soccal7, Benjamin J Marsland1, Laurent P Nicod1.
Abstract
BACKGROUND: Homeostatic turnover of the extracellular matrix conditions the structure and function of the healthy lung. In lung transplantation, long-term management remains limited by chronic lung allograft dysfunction, an umbrella term used for a heterogeneous entity ultimately associated with pathological airway and/or parenchyma remodeling.Entities:
Keywords: Airway remodeling; fibroblasts; macrophages; matrix; microbiota
Mesh:
Year: 2017 PMID: 28729000 PMCID: PMC5792246 DOI: 10.1016/j.jaci.2017.06.022
Source DB: PubMed Journal: J Allergy Clin Immunol ISSN: 0091-6749 Impact factor: 10.793
Patient characteristics
| Patients/samples | Total, no. | 116/189 |
| Male | 58 (50.0) | |
| Age at transplant (y) | 52 (35, 61) | |
| Sampling time point (days posttransplantation) | 339 (92, 376) | |
| Type of transplant | Bilateral lung | 101 (87.0) |
| Single lung | 15 (12.9) | |
| Pretransplantation diagnosis | Chronic obstructive pulmonary disease | 38 (32.8) |
| Cystic fibrosis | 31 (26.7) | |
| Interstitial lung disease | 24 (20.7) | |
| Graft failure (retransplantation) | 5 (4.3) | |
| Other | 18 (15.5) | |
| Transbronchial biopsies | 167 (88.4) | |
| A0 | 128 (76.6) | |
| A1 | 21 (12.6) | |
| A2 | 5 (3.0) | |
| B0 | 105 (62.9) | |
| B1 | 19 (11.4) | |
| B2 | 1 (0.6) | |
| Immunosuppression | Tacrolimus | 176 (93.1) |
| Cyclosporin | 13 (6.9) | |
| Antibiotics | TMP/SMX | 143 (75.7) |
| Azithromycin | 25 (13.2) | |
| Other (inhaled, oral, or intravenous routes) | 54 (28.6) | |
| BAL positive bacterial culture (excludes oropharyngeal flora) | 32 (16.9) | |
| BAL positive fungal culture | 13 (6.9) | |
| BAL positive viral PCR | CMV (n = 11), EBV (n = 2), metapneumovirus (n = 1), parainfluenza (n = 1) | 14 (13.2) |
Data presented as n (% of group) or median (IQR) unless otherwise indicated.
CMV, Cytomegalovirus; TMP/SMX, trimethoprim/sulfamethoxazole.
At sampling.
Grading of pulmonary allograft rejection according to guidelines of the International Society for Heart and Lung Transplantation.
Conducted in a subset (n = 106) of samples. Virological investigations ranged from CMV only to more extensive testing, as per case requirement.
Fig 1Identification of a set of remodeling genes. A, Schematic outline of experimental approach. B, GO criteria used in candidate gene selection process. C, Principal component (PC) analysis, and associated eigenvectors, based on quantitative PCR determination of expression of the restricted list of 11 remodeling genes (see Table II for details) in the initial subset of 9 BAL samples (dots).
Remodeling gene set used for the characterization of BAL cell profiling∗
| Gene name, alias | Gene symbol | Molecular functions |
|---|---|---|
| Chitinase 3-like 1 | CHI3L1 | Regulator of cell-matrix interactions |
| Collagen type VI α-2 chain | COL6A2 | Matrix constituent |
| Fibronectin 1 | FN1 | Matrix constituent |
| Insulin-like growth factor 1 | IGF1 | Fibroblast proliferation and activation |
| Insulin-like growth factor binding protein 2 | IGFBP2 | Fibroblast proliferation and activation |
| Matrix metallopeptidase 7 | MMP7 | Mediator of matrix turnover; basement membrane proteolysis |
| Matrix metallopeptidase 9 | MMP9 | Mediator of matrix turnover; collagen and fibronectin proteolysis |
| Matrix metallopeptidase 12 | MMP12 | Mediator of matrix turnover; elastin proteolysis |
| Platelet-derived growth factor D | PDGFD | Fibroblast proliferation and survival |
| Secreted phosphoprotein 1, osteopontin | SPP1 | Regulator of cell-matrix interactions |
| Thrombospondin 1 | THBS1 | Regulator of cell-matrix interactions; major activator of TGF-β1 |
Primer and probe sequences are available in Table E1 in this article's Online Repository.
According to Human Gene Organization (HUGO) Gene Nomenclature Committee at the European Bioinformatics Institute.
Oligonucleotide primers and probes for analysis of BAL cell profiling
| Oligonucleotide name | NCBI gene ID | NCBI reference sequence | 5′ label | Sequence |
|---|---|---|---|---|
| CHI3L1_forward | — | 5′-GATTTTCATGGAGCCTGGCG-3′ | ||
| CHI3L1_reverse | 1116 | NM_001276.2 | — | 5′-CCCCACAGCATAGTCAGTGTT-3′ |
| CHI3L1_probe | Tx Red | 5′-ACAGGCCATCACAGTCCCCTGTTCCGA-3′ | ||
| COL6A2_forward | — | 5′-AGCTCTACCGCAACGACTAC-3′ | ||
| COL6A2_reverse | 1292 | NM_001849.3 | — | 5′-CACCTTGTAGCACTCTCCGT-3′ |
| COL6A2_probe | FAM | 5′-ACTCCACCGAGATCGACCAGGACACCA-3′ | ||
| MMP7_forward | — | 5′-AAGTGGTCACCTACAGGATCG-3′ | ||
| MMP7_reverse | 4316 | NM_002423.4 | — | 5′-TCAGCAGTTCCCCATACAACT-3′ |
| MMP7_probe | Cy5 | 5′-ACATGTGGGGCAAAGAGATCCCCCTGC-3′ | ||
| MMP9_forward | — | 5′-GTACTCGACCTGTACCAGCG-3′ | ||
| MMP9_reverse | 4318 | NM_004994.2 | — | 5′-AACAAACTGTATCCTTGGTCCG-3′ |
| MMP9_probe | HEX | 5′-ACAGCGACAAGAAGTGGGGCTTCTGCC-3′ | ||
| IGF1_forward | — | 5′-GCTTTTATTTCAACAAGCCCACAG-3′ | ||
| IGF1_reverse | 3479 | NM_001111283.2 | — | 5′-GCCTCCTTAGATCACAGCTCC-3′ |
| IGF1_probe | HEX | 5′-ACAGGCATCGTGGATGAGTGCTGCTTCC-3′ | ||
| IGFBP2_forward | 5′-AACCTCAAACAGTGCAAGATGTC-3′ | |||
| IGFBP2_reverse | 3485 | NM_000597.2 | 5′-GTAGAAGAGATGACACTCGGGG-3′ | |
| IGFBP2_probe | Tx Red | 5′-AGCGTGGGGAGTGCTGGTGTGTGAA-3′ | ||
| SPP1_forward | 5′-TAAATTCTGGGAGGGCTTGGTT-3′ | |||
| SPP1_reverse | 6696 | NM_001040060.1 | 5′-CATGGTAGTGAGTTTTCCTTGGTC-3′ | |
| SPP1_ probe | Cy5 | 5′-AGGCCAGTTGCAGCCTTCTCAGCCA-3′ | ||
| THBS1_forward | 5′-GGAGGAGGGGTACAGAAACG-3′ | |||
| THBS1_reverse | 7057 | NM_003246.3 | 5′-CAGGCATCCATCAATTGGACAG-3′ | |
| THBS1_ probe | FAM | 5′-ACCCCAGTTTGGAGGCAAGGACTGCGT-3′ | ||
| FN1_forward | — | 5′-GGCTGGAGCCGGGCATTGAC-3′ | ||
| FN1_reverse | 2335 | NM_212482.1 | — | 5′-GGGAGGAGGAACAGCCGTTTGTT-3′ |
| FN1_probe | Tx Red | 5′-TGTAGTAGGGGCACTCTCGCCGCCA-3′ | ||
| MMP12_forward | 5′-TGCCCGTGGAGCTCATGGAGAC-3′ | |||
| MMP12_reverse | 4321 | NM_002426.4 | 5′-CCTCCAATGCCAGATCCAGGTCCAA-3′ | |
| MMP12_ probe | HEX | 5′-AGCATGGGCTAGGATTCCACCTTTGCCATCA-3′ | ||
| PDGFD_forward | 5′-CCTCAGGCGAGATGAGAGCAATCAC-3′ | |||
| PDGFD_reverse | 80310 | NM_025208.4 | 5′-TTCCTGGGGTAGCTGTTCGGGA-3′ | |
| PDGFD_ probe | Cy5 | 5′-TGCACGTAGCCGTTTCCTTTCACCTGG-3′ | ||
| GNB2L1_forward | — | 5′-CCAGCAGCAAGGCAGAACCACC-3′ | ||
| GNB2L1_reverse | 10399 | NM_006098.4 | — | 5′-ACACTCGCACCAGGTTGTCCG-3′ |
| GNB2L1_probe | Cy5.5 | 5′-TGCACCTCCCTGGCCTGGTCTGCT-3′ |
The primers and probes specific for CHI3L1, COL6A2, MMP7, MMP9; IGF1, IGFBP2, SPP1, THBS1; and FN1, MMP12, PDGFD were collectively used in multiplex-1, -2, and -3, respectively. The primers and probe specific for GNB2L1, our reference gene, were added into each multiplex.
Cy, Cyanine; FAM, fluorescein; GNB2L1, guanine nucleotide-binding protein, β-polypeptide 2-like 1; HEX, hexachloro-fluorescein; Tx Red, Texas Red.
Fig 2Identification of 4 remodeling gene expression profiles in posttransplantation BAL samples. PC analysis (A) and hierarchical clustering (B) based on qPCR determination of gene expression (C). Medians and IQRs are indicated. *P < .05, **P < .01, ***P < .001, and ****P < .0001. Transversal (D) and intraindividual (E) posttransplantation variations in remodeling gene expression profile. E, Data show the frequency of sample pairs that displayed acquisition of a new remodeling profile. F, Schematic diagram of intraindividual remodeling profile transitions with indicated occurrences.
Fig E1Spearman correlation coefficient matrix based on expression levels of the selected 11 remodeling genes. Gene names are listed in Table II. Data are presented as Spearman ρ with P value, obtained by analyzing by quantitative PCR expression of the 11 selected genes in the total set of 187 BAL samples.
Timing of BAL sample collection in patients with multiple lavages
| 0.5-3 | 3-6 | 6-12 | 12-24 | Total samples | |
|---|---|---|---|---|---|
| Pat. 1 | 1 | 1 | 2 | ||
| Pat. 2 | 2 | 1 | 3 | ||
| Pat. 3 | 2 | 2 | 2 | 6 | |
| Pat. 4 | 2 | 1 | 3 | ||
| Pat. 5 | 2 | 2 | |||
| Pat. 6 | 2 | 2 | 4 | ||
| Pat. 7 | 2 | 1 | 3 | ||
| Pat. 8 | 2 | 2 | 2 | 6 | |
| Pat. 9 | 2 | 2 | |||
| Pat. 10 | 2 | 1 | 3 | ||
| Pat. 11 | 2 | 2 | 4 | ||
| Pat. 12 | 2 | 2 | |||
| Pat. 13 | 1 | 2 | 1 | 4 | |
| Pat. 14 | 1 | 1 | 2 | ||
| Pat. 15 | 1 | 1 | 2 | ||
| Pat. 16 | 1 | 1 | 2 | ||
| Pat. 17 | 2 | 1 | 1 | 4 | |
| Pat. 18 | 2 | 2 | 1 | 5 | |
| Pat. 19 | 1 | 1 | 2 | ||
| Pat. 20 | 1 | 1 | 1 | 3 | |
| Pat. 21 | 2 | 2 | |||
| Pat. 22 | 2 | 2 | 1 | 5 | |
| Pat. 23 | 2 | 1 | 1 | 4 | |
| Pat. 24 | 2 | 2 | |||
| Pat. 25 | 2 | 2 | 1 | 5 | |
| Pat. 26 | 2 | 2 | 1 | 5 | |
| Pat. 27 | 1 | 2 | 1 | 4 | |
| Pat. 28 | 2 | 1 | 1 | 1 | 5 |
| Pat. 29 | 2 | 2 | |||
| Pat. 30 | 1 | 1 | 2 | ||
| Pat. 31 | 1 | 1 | 2 | ||
| Pat. 32 | 1 | 1 | 2 | ||
| Pat. 33 | 1 | 1 | 2 | ||
| Pat. 34 | 1 | 1 | 2 |
Time window posttransplantation (months).
Patient code.
Fig 3Associations between the pulmonary microbiota and host remodeling gene expression. Microbiota status (A), the 10 most abundant microbial genera (B), Shannon diversity index with medians and IQRs, *P < .05 (C) and culture outcome (D) as per remodeling profile. E, Kinetics of microbiota status posttransplantation. F, Bray-Curtis principal coordinate (PCo) analysis of inferred metagenomic content. G, Differential abundance analysis focused on KOs related to bacteria-matrix interaction or proteolysis, on a catabolic versus anabolic remodeling gene expression background.
Sample distribution based on transbronchial biopsy evaluation∗
| Grade | Low | Anabolic | Intermediate | Catabolic | Firmi/Proteo/Actino dysbiosis | No dysbiosis | Bact dysbiosis | |
|---|---|---|---|---|---|---|---|---|
| Acute rejection | A0 | 28 (80) | 24 (80) | 57 (86.4) | 13 (81.3) | 20 (87) | 84 (81.5) | 24 (92.3) |
| A1 (minimal) | 5 (14.3) | 6 (20) | 7 (10.6) | 3 (18.7) | 3 (13.0) | 16 (15.6) | 1 (3.8) | |
| A2 (mild) | 2 (5.8) | 0 (0) | 2 (3) | 0 (0) | 0 (0) | 3 (2.9) | 1 (3.8) | |
| Airway inflammation | B0 | 31 (88.6) | 22 (84.6) | 57 (89.1) | 11 (78.6) | 13 (72.2) | 69 (84.1) | 20 (95.2) |
| B1-B2 (low grade) | 4 (11.4) | 4 (15.4) | 7 (10.9) | 3 (21.4) | 5 (27.8) | 13 (15.9) | 1 (4.8) |
Data presented as n (%) within each BAL cell gene expression profile or microbiota composition group.
Actino, Actinobacteria; Bact, Bacteroidetes; Firmi, Firmicutes; Proteo, Proteobacteria.
Grading of pulmonary allograft rejection according to guidelines of the International Society for Heart and Lung Transplantation.
Fig 4Associations among host remodeling, inflammation, and infection. Relationship among host remodeling and BAL cell differential (A), expression of inflammatory genes COX2 and TNF-α (B), prevalence of suspected clinical infection (C), and bacteria isolated by culture and/or driving dysbiosis (D). In panels A and B, medians and IQRs are indicated. *P < .05, **P < .01, ***P < .001, and ****P < .0001.
Fig E2Cell viability determined in fibroblast-THP-DM cocultures, either in the absence (no bacteria) or presence of bacterial mixtures, as indicated. Data were pooled from 3 independent experiments with duplicates. Values (mean ± SEM) were normalized to viability levels in the absence of bacteria. Statistical significance was determined using Friedman test and Dunn post hoc analysis.
Fig 5Impact of bacterial stimulation on remodeling gene expression in macrophage-fibroblast cocultures. A, Gene expression-based PC analysis. Dots represent the mean coordinates obtained from duplicates in 3 independent experiments. B, Quantitative PCR-based gene expression analysis. Immunostaining (C) and quantification (D) of deposited matrix proteins. Scale bar represents 100 μm. B-D, Data were from 6 independent experiments. Values represented as mean with SEM are expressed as fold-change over baseline. *P < .05, **P < .01, and ***P < .001.